GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GC Cell Corp (XKRX:144510) » Definitions » EV-to-EBIT

GC Cell (XKRX:144510) EV-to-EBIT : 115.73 (As of May. 23, 2024)


View and export this data going back to 2016. Start your Free Trial

What is GC Cell EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, GC Cell's Enterprise Value is ₩624,358 Mil. GC Cell's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩5,395 Mil. Therefore, GC Cell's EV-to-EBIT for today is 115.73.

The historical rank and industry rank for GC Cell's EV-to-EBIT or its related term are showing as below:

XKRX:144510' s EV-to-EBIT Range Over the Past 10 Years
Min: -3631.79   Med: 67.17   Max: 1238.51
Current: 115.73

During the past 11 years, the highest EV-to-EBIT of GC Cell was 1238.51. The lowest was -3631.79. And the median was 67.17.

XKRX:144510's EV-to-EBIT is ranked worse than
96.12% of 103 companies
in the Medical Diagnostics & Research industry
Industry Median: 22.43 vs XKRX:144510: 115.73

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. GC Cell's Enterprise Value for the quarter that ended in Mar. 2024 was ₩638,224 Mil. GC Cell's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩5,395 Mil. GC Cell's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 0.85%.


GC Cell EV-to-EBIT Historical Data

The historical data trend for GC Cell's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GC Cell EV-to-EBIT Chart

GC Cell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -127.05 172.60 39.45 19.06 -189.85

GC Cell Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 275.70 -165.77 -34.16 -189.85 118.30

Competitive Comparison of GC Cell's EV-to-EBIT

For the Diagnostics & Research subindustry, GC Cell's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GC Cell's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GC Cell's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GC Cell's EV-to-EBIT falls into.



GC Cell EV-to-EBIT Calculation

GC Cell's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=624357.593/5394.738
=115.73

GC Cell's current Enterprise Value is ₩624,358 Mil.
GC Cell's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩5,395 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GC Cell  (XKRX:144510) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

GC Cell's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=5394.738/638224.241
=0.85 %

GC Cell's Enterprise Value for the quarter that ended in Mar. 2024 was ₩638,224 Mil.
GC Cell's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩5,395 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GC Cell EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of GC Cell's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


GC Cell (XKRX:144510) Business Description

Traded in Other Exchanges
N/A
Address
30 beongil to giheung-gu, Gyeonggi, 107 Lee Hyun, Yongin, KOR, 16 924
GC Cell Corp engages in the provision of anti-cancer immunotherapy. The company is developing an anticancer drug, which is in Phase II clinical trials; and stem cell treatment drugs. It also provides cell banking, sample inspection, clinical trial, and bio logistics services.

GC Cell (XKRX:144510) Headlines

No Headlines